Urinary Crosslinked N-telopeptides of type I collagen (NTx) among Reproductive and Post-menopausal Thai women

Article Sidebar

pdf
Published: Apr 30, 2010
Keywords:
Urinary NTx bone turnover marker Crosslinked N-telopeptides of type I collagen menopause osteoporosis

Main Article Content

Sangkarak P, MD
Department of Orthopaedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Arpornchayanon O, MD
Department of Orthopaedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Kongtawelert P, PhD
Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Luevitoonvechkij S, MD
Department of Orthopaedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Chanmee T, MS
Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Abstract

Purpose: To study the level of Urinary Crosslinked N-telopeptides of type I collagen (Urinary NTx) in reproductive and postmenopausal Thai women and their correlation with bone mineral density (BMD) and duration after menopause.


Methods: Second or third void morning urine samples were collected in 48 reproductive women and 42 postmenopausal women. Urinary NTx was measured by competitive-inhibition ELISA and corrected with spot urine creatinine. BMD was measured in all postmenopausal participants.


Results: The mean value of Urinary NTx in reproductive women was 36.19 nanomoles of bone collagen equivalents per millimole of Creatinine (nM BCE/mM Cr), standard deviation = 25.18 with 95% confidence interval = 28.88 to 43.50 nM BCE/mM Cr. The mean value of Urinary NTx in postmenopausal women was 58.89 nM BCE/mM Cr, standard deviation = 26.93 with 95% confidence interval = 50.50 to 67.28 nM BCE/mM Cr. Neither BMD nor duration after menopause is significantly correlated with Urinary NTx.


Conclusion: Urinary NTx increased with age in Thai women (p<0.0001). A significant change was observed in postmenopausal women compared to reproductive women (p<0.0001).

Article Details

Issue
Vol. 34 No. 1-2 (2010): January-April
Section
Original Articles

References

1. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20(6): 843-51.
2. Stork S, Stork C, Angerer P, Kothny W, Schmitt P, Wehr U, et al. Bone sialoprotein is a specific biochemical marker of bone metabolism in postmenopausal women: a randomized 1-year study. Osteoporos Int. 2000; 11(9): 790-6.
3. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, Committee of Scientific Advisors of the International Osteoporosis Foundation (2000). The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int.. 2000; 11(6): 2–17.
4. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int. 2007; 18(5): 681-5.
5. Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest. 2005; 28(10): 8-13.
6. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122.
7. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992; 7(11): 1251-8.
8. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999; 14(5): 792-801.
9. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994; 9(2): 135-42.
10. Abe Y, Ishikawa H, Fukao A. Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. Tohoku J Exp Med. 2008; 214(1): 51-9.
11. Seibel MJ. Biochemical Markers of Bone Turnover Part II: Clinical Applications in the Management of Osteoporosis. Clin Biochem Rev. 2006; 27(3): 123-38.
12. Bunyaratavej N. Monitoring of Risedronate by biochemical bone markers in clinical practice. J Med Assoc Thai. 2005; 88(5): 34-6.
13. Bunyaratavej N, Kittimanon N. Study of procollagen type1 nitrogenous propeptides (P1NP) in reproductive female. J Med Assoc Thai. 2005; 88(5): 27-8.
14. Bunyaratavej N, Soontrapa S, Rojanasthin S, Kitimanon N, Lektrakul S. Level of undercarboxylated osteocalcin in reproductive Thai females. J Med Assoc Thai. 2005; 88(5): 37-9.
15. Soontrapa S, Soontrapa S, Bunyaratavej N. Serum concentration of undercarboxylated osteocalcin and the risk of osteoporosis in thai elderly women. J Med Assoc Thai. 2005; 88( 5): 29-32.
16. Bunyaratavej N, Kitimanon N, Boonthitikul S. Study of the level of biochemical bone markers: NMID osteocalcin and bone resorptive marker (beta CTx) in Thai women. J Med Assoc Thai. 2001; 84(2): 560-5.
17. Sone T, Miyake M, Takeda N, Fukunaga M. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits. Bone. 1995; 17(4): 335-9.
18. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6): 785–95.
19. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843: 1-129.